Toward an optimal joint recognition of the s1′ subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP)

Journal of Medicinal Chemistry

Volumn 45, Issue 7, 2002, Pages 1477-1486

  Inguimbert, Nicolas ^a   Coric, Pascale ^a   Poras, Hervé ^a   Meudal, Hervé ^a   Teffot, Franck ^a   Fournié Zaluski, Marie Claude ^a   Roques, Bernard P ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CAPTOPRIL; CGS 31447; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; ENZYME INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; THIOL DERIVATIVE; THIORPHAN; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; ZINC DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; FLUID BALANCE; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; NONHUMAN; RAT; STEREOCHEMISTRY; STEREOISOMERISM;

EID: 0037187403     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0005454     Document Type: Article

References (39)

1. Cell surface metallopeptidases involved in blood pressure regulation: Structure, inhibition and clinical perspectives
2. ACE, NEP and ECE-1: Selective and combined inhibition
3. Angiotensin converting enzyme inhibitors
4. Neutral endopeptidase 24.11. Structure, inhibition and experimental and clinical pharmacology
5. Recent advances in the design and development of vasopeptidase inhibitors
6. Design of specific inhibitors of angiotensin converting enzyme. New class of orally active antihypertensive agents
7. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice
8. Potent and selective nonpeptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action
9. Lisinopril: A review of its use in congestive heart failure
10. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure
11. Neutral endopeptidase-24.11 inhibitors: From analgesics to antihypertensives
12. Role of neutral endopeptidase in the metabolism of endothelin
13. Solid-phase synthesis of phosphinic acid endothelin converting enzyme inhibitors
14. New dual inhibitors of neutral endopeptidase and angiotensin converting enzyme: Rational design, bioavaibility, and pharmacological responses in experimental hypertension
15. [1H]NMR configuration correlation for retro-inverso dipeptides: Application to the determination of the absolute configuration of "enkephalinase" inhibitors. Relationships between stereochemistry and enzyme recognition
16. Endothelin-converting enzymes
17. Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon
18. A three-dimensional model of endothelin-converting enzyme (ECE) based on the x-ray structure of neutral endopeptidase 24.11 (NEP)
19. Three-dimensional models of ACE and NEP inhibitors their use in the design of potent dual ACE/NEP inhibitors
20. Molecular modelling and site directed mutagenesis of the active site of endothelin-converting enzyme
21. Thiol inhibitors of endothelin converting enzyme
22. Exploration of the S1′ subsite of neprilysin: A joined molecular and site-directed mutagenesis study
23. Relationship between the inhibitory potencies of thiorphan and retrothiorphan enantiomers on thermolysin and neutral endopeptidases 24.11 and their interactions with the thermolysin active site by computer modeling
24. Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11
25. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11 and angiotensin-converting enzyme
26. Endothelin converting enzyme inhibitors
27. Design and synthesis of potent thiol-based inhibitors of endothelin-converting enzyme-1
28. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS-35,066
29. (Dipropylphenoxy) phenylacetic acids: A new generation of non peptidic angiotensin II receptor antagonists
30. Tandem Michael addition alkylation of vinylphosphonates
31. Über kondensationen in der reihe der arylacetonitrile
32. Migration du groupe ethoxycarbonyle dans la transposition de Wagner-Meerwein
33. The use of a monoclonal antibody for the high yield purification of kidney enkephalinase solubilized in β-octylglucoside
34. Affinity chromatographic purification of angiotensin converting enzyme
35. Very sensitive and selective fluorescent assays for high throughput screening of endothelin converting enzyme inhibitors
36. 2)Phe-β-ala, a specific fluorogenic substrate for neutral endopeptidase 24.11
37. Studies of the angiotensin converting enzyme with different substrates